(Q84114246)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

Maurie Markman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

24 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

6-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.017

10.1016/J.YGYNO.2010.03.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20421127%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference